BACKGROUND: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported. OBJECTIVE: We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab. RESULTS AND CONCLUSION: In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2 months post-infusion.
BACKGROUND:Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). Although Immune thrombocytopenia (ITP) has been reported as a secondary autoimmune phenomenon following alemtuzumab infusion, immediate thrombocytopenia during the infusion has not been reported. OBJECTIVE: We report transient, reversible, self-limiting acute-onset thrombocytopenia during the first course with alemtuzumab. RESULTS AND CONCLUSION: In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2 months post-infusion.
Authors: Eva Havrdova; Jeffrey A Cohen; Dana Horakova; Ivana Kovarova; Eva Meluzinova Journal: Ther Clin Risk Manag Date: 2017-10-16 Impact factor: 2.423
Authors: Adam Cuker; Ann D Bass; Congor Nadj; Mark A Agius; Brian Steingo; Krzysztof W Selmaj; Timothy Thoits; Alexandre Guerreiro; Bart Van Wijmeersch; Tjalf Ziemssen; Sven G Meuth; Christopher C LaGanke; Karthinathan Thangavelu; Claudio E Rodriguez; Darren P Baker; David H Margolin; Ann Jannsens Journal: Mult Scler Date: 2019-02-20 Impact factor: 6.312